Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15742958 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL29214583 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL20970529 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL29206701 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL19015480 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL23579480 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL16374503 | 1.00 | HPGD (0.49) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL29959190 | 0.90 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL29959102 | 0.90 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL12589175 | 0.89 | HPGD (0.50) | HPGDRECQLEPHX1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-4359400-B1 | SALT AND CRYSTAL FORM OF AN AZETIDINYL SUBSTITUTED ISOQUINLINE ACTING AS EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR FOR THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORP (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4514803-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| CN-119019367-A | Pyrimidine compound, preparation method thereof, pharmaceutical composition and application | 中国药科大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-118834213-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240308981-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-09-19 | — | — | US | disclosed |
| US-20170183342-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC | 2017-06-29 | — | — | US | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2922851-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081718-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183342-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM5, CHRM4, CHRM1 | HPGD 1284/4885RECQL 1541/4885EPHX1 824/4885 |
| US-20250129047-A1 | ISOQUINOLINE DERIVATIVES AS MUTANT EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB4 | HPGD 2960/4885RECQL 170/4885EPHX1 1164/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-20240308981-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | HPGD 821/4885RECQL 3644/4885EPHX1 2135/4885 |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | HPGD 4109/4885RECQL 982/4885EPHX1 2868/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | HPGD 1397/4885RECQL 2903/4885EPHX1 1768/4885 |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | HPGD 3904/4885RECQL 2451/4885EPHX1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.